Macro partitioning
Tirzepatide treatment for obesity results in a 3:1 ratio of fat mass reduction to fat-free mass (FFM) reduction, leading to improved body composition rather than proportional lean tissue loss.
If you are using Tirzepatide for weight loss, you can expect your body composition to improve favorably. The medication targets fat stores more aggressively than lean muscle tissue, resulting in roughly three times more fat loss than muscle loss. This helps maintain your metabolic rate and physical function better than traditional caloric restriction alone, which often depletes lean mass proportionally.
The exposure–response model revealed that administration of tirzepatide resulted in three times greater reduction of fat mass than that of FFM. This differential effect resulted in improved body composition over time.
Why this rating
Based on a large Phase 3 trial (n=2,539) with external validation against DXA scans in a subset, though FFM/Fat mass were calculated via model rather than direct measurement for the majority.
Source
A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure–Response Relationship during Treatment of Obesity with Tirzepatide
Emmanuel Chigutsa et al. · Clinical Pharmacology & Therapeutics · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →